[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Leithold et al., 2016 - Google Patents

Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease

Leithold et al., 2016

Document ID
1707388442647370320
Author
Leithold L
Jiang N
Post J
Niemietz N
Schartmann E
Ziehm T
Kutzsche J
Shah N
Breitkreutz J
Langen K
Willuweit A
Willbold D
Publication year
Publication venue
European journal of pharmaceutical sciences

External Links

Snippet

Peptides are more and more considered for the development of drug candidates. However, they frequently exhibit severe disadvantages such as instability and unfavourable pharmacokinetic properties. Many peptides are rapidly cleared from the organism and oral …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Leithold et al. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease
Schroeder et al. The disaccharide moiety of bleomycin facilitates uptake by cancer cells
Roxin et al. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides
Scarf et al. The translocator protein (18 kDa): central nervous system disease and drug design
Lacy et al. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites
Ebenhan et al. Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT
Boros et al. Evaluation of the H2 dedpa scaffold and its cRGDyK conjugates for labeling with 64Cu
Leithold et al. Pharmacokinetic properties of a novel D-peptide developed to be therapeutically active against toxic β-amyloid oligomers
Luurtsema et al. Evaluation of [11C] laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats
Synold et al. Single-dose pharmacokinetic and toxicity analysis of pyrrole–imidazole polyamides in mice
Sun et al. Mirror image phage display–Generating stable therapeutically and diagnostically active peptides with biotechnological means
Achilefu et al. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors
Mokaleng et al. Synthesis, 68Ga‐Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide‐Derived Compound as a Potential PET/CT Infection Imaging Agent
Barone et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line
Serdons et al. Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β
Laube et al. Synthesis and preliminary radiopharmacological characterisation of an 11C‐labelled azadipeptide nitrile as potential PET tracer for imaging of cysteine cathepsins
Wuest et al. Radiopharmacological evaluation of 18F-labeled phosphatidylserine-binding peptides for molecular imaging of apoptosis
Ishiwata et al. Evaluation of (+)-p-[11C] methylvesamicol for mapping sigma1 receptors: a comparison with [11C] SA4503
Gan et al. Development of a 18F-labeled bicyclic peptide targeting EphA2 for molecular imaging of PSMA-negative prostate cancer
Malik et al. Development and biological evaluation of [18F] FMN3PA & [18F] FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging
García Boy et al. Sunflower trypsin inhibitor 1 derivatives as molecular scaffolds for the development of novel peptidic radiopharmaceuticals
Keller et al. Prototypic 18F-labeled argininamide-type neuropeptide Y Y1R antagonists as tracers for PET imaging of mammary carcinoma
Boschi et al. Asymmetrical nitrido Tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors
Oh et al. Direct Fluorination Strategy for the Synthesis of Fluorine‐18 Labeled Oligopeptide—[18F] ApoPep‐7
Chiotellis et al. Synthesis and preliminary biological evaluation of O-2 ((2-[18 F] fluoroethyl) methylamino) ethyltyrosine ([18 F] FEMAET) as a potential cationic amino acid PET tracer for tumor imaging